AbbVie Announces Global Resolution of HUMIRA(R) (adalimumab) Patent Disputes with Fresenius Kabi

Agreements Provide Non-Exclusive License to Fresenius Kabi for HUMIRA-Related Intellectual Property in the U.S. Effective September 30, 2023, and in Other Markets on Different Dates Fresenius Kabi Acknowledges Validity of AbbVie's Intellectual Property ... Biopharmaceuticals, Litigation, Licensing AbbVie, Fresenius Kabi, HUMIRA, adalimumab
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Humira | Pharmaceuticals